Seer Inc Dossier
Qualitative Analysis
Business overview
Seer, Inc. (Nasdaq: SEER) is a life sciences company focused on developing and commercializing innovative technologies to decode the biology of the proteome. The company's flagship offering, the Proteograph Product Suite, integrates proprietary engineered nanoparticles, automated instrumentation, consumables, and advanced analytical software to enable deep, rapid, unbiased, and large-scale proteomics. Seer's products are marketed for research use only and are utilized by academic institutions, life sciences laboratories, and biopharmaceutical companies. Co-founded by CEO Dr. Omid C. Farokhzad, the company is headquartered in Redwood City, California.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
A commercial program designed to lower the barrier to entry for capital-constrained customers by allowing them to leverage operating budgets for consumables while Seer places the Proteograph instruments.
Expected impact: Accelerates the expansion of the installed base and drives long-term high-margin consumables utilization.
A service-based initiative allowing customers to run samples in their own labs and have Seer run the mass spectrometry, or providing end-to-end sample-to-data services.
Expected impact: Lowers the adoption barrier for the Proteograph product suite; approximately half of the instrument installs in 2025 were from previous STAC customers.
Development of a proprietary next-generation proteomics detector to create an integrated, end-to-end sample-to-data proteomics solution.
Expected impact: Aims to expand the addressable market significantly beyond existing mass spectrometry users.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Enables Thermo Fisher's global sales force to quote and sell Seer's Proteograph Product Suite alongside Thermo Scientific Orbitrap Astral mass spectrometers, creating a seamless sample-to-data workflow.
Terms: Non-exclusive agreement; specific financial splits are not publicly disclosed.
Provides deep, unbiased proteomics on 10,000 samples for the PRECISE-SG100K study, a landmark multi-ancestry population-scale cohort of 100,000 Singapore residents.
Terms: Collaborative research agreement; specific financial terms are not disclosed.
A three-year population-level study analyzing 20,000 clinical plasma samples using the Proteograph ONE Assay and SP200 Automation Instrument to develop AI-driven diagnostics for early-onset cancers.
Terms: Funded by the K-Health MIRAE initiative under the Ministry of Health and Welfare, Republic of Korea.